Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term taxol. Found 33 abstracts

no pagination
Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Oncotargets and Therapy. 2012 Jan;5:161-70.   PMCID: PMC3430391
Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Movsas B, Byhardt RW. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. Journal of Clinical Oncology. 2005 Aug;23(22):4991-8.
Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Seminars in Radiation Oncology. 1999 Apr;9(2):108-16.
Socinski MA, Langer CJ. Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. Seminars in Oncology. 1999 Oct;26(5):51-61.
Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Research. 1999 Aug;59(15):3663-70.
Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. British Journal of Cancer. 1998 Feb;77(4):562-6.
Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Cloning and sequencing of human beta(III)-tubulin cDNA: induction of beta(III) isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochimica Et Biophysica Acta-Gene Structure and Expression. 1998 Jan 21;1395(2):237-45.
Sangrajrang S, Denoulet P, Laing NM, Tatoud R, Millot G, Calvo F, Tew KD, Fellous A. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochemical pharmacology. 1998 Feb;55(3):325-31.
Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Seminars in Oncology. 1997 Dec;24(6):S13-S15.
Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Annals of Oncology. 1997 Jun;8(6):611-4.
Laing N, Dahllof B, HartleyAsp B, Ranganathan S, Tew KD. Interaction of estramustine with tubulin isotypes. Biochemistry. 1997 Jan 28;36(4):871-8.
Langer CJ. The emerging role of paclitaxel and carboplatin in non-small cell lung carcinoma. In: Updates in Advances in Lung Cancer. 1997. p. 73-90.
Oreilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A gynecologic oncology group study. Journal of Clinical Oncology. 1997 Jan;15(1):177-86.
Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, Odwyer P, Rowinsky E, Gallion HH, Ozols RF. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. Journal of Clinical Oncology. 1996 Jun;14(6):1895-902.
Essayan DM, KageySobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. Journal of Allergy and Clinical Immunology. 1996 Jan;97(1):42-6.
Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, Odwyer PJ, Gallo JM. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clinical Cancer Research. 1996 Mar;2(3):549-52.
Zhang XQ, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Molecular Pharmacology. 1996 Feb;49(2):288-94.
Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase-I Study of Paclitaxel and Estramustine - Preliminary Activity in Hormone-Refractory Prostate-Cancer. Seminars in Oncology. 1995 Jun;22(3):6-11.
Langer CJ, Leighton JC, Comis RL, Odwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF. Paclitaxel by 24- or 1-Hour Infusion in Combination with Carboplatin in Advanced Nonsmall Cell Lung-Cancer - the Fox Chase Cancer Center Experience. Seminars in Oncology. 1995 Aug;22(4):18-29.
Langer CJ, Leighton JC, Comis RL, Odwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF. Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-Small-Cell Lung-Cancer - a Phase-Ii Toxicity, Response, and Survival Analysis. Journal of Clinical Oncology. 1995 Aug;13(8):1860-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term taxol

taxol cancer carcinoma cisplatin estramustine vinblastine cooperative-oncology-group chemotherapy randomized trial phase-ii paclitaxel beta-tubulin therapy trial binding drug resistance microtubule dynamics phase-i trial tubulin 3-hour infusion bovine brain microtubule assembly invitro carcinoma cell-lines sensitizer radiation sensitizer ifosfamide p53 function previously untreated patients plus carboplatin lung-cancer cyclophosphamide agent carboplatin creatinine clearance drug dexamethasone hypersensitivity reactions tubulin isotype protein farnesyltransferase radiation-therapy prostatic cell lines monoclonal-antibody inhibitor suramin refractory prostate-cancer paclitaxel pancreas cancer-gemcitabine-irradiation polyglutamylation nuclear hyperfractionated radiation-therapy hypersensitivity prostatic-carcinoma dosage metaanalysis 1993 oy h-cancer-v71-p3774 kinetic stabilization in-vitro histamine release vinorelbine alpha-tubulin isotype expression survival 4-dichlorobenzyl thiocyanate tumors colchicine binding vp-16 concurrent radiation serum creatinine proteins accumulation expression mechanism cremophor-el phenotype hyperfractionated radiation- disease randomized guanosine 5'-triphosphate histamine-release pharmacology cremophor du-145 phosphate estracyt long dna human basophils proliferation local-control 3-hour microtubule-associated proteins infusion binds isotypes 2 assembly invitro growth stage-iii cyto-toxicity antimitotic agent concurrent capecitabine multidrug-resistance desensitization acute-leukemia
Last updated on Monday, July 06, 2020